NASDAQ:IMNM | Free Cash Flow | Immunome Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$58.64M$3M-$61.64M
2025-12-31-$47.95M$4M-$51.95M
2025-03-31-$53.06M$3.67M-$56.72M
2024-12-31-$42.06M$1.13M-$43.19M
2024-03-31-$11.17M$2.16M-$13.33M
2023-12-31-$17.46M$349,000.00-$17.81M
2023-03-31$24.17M$106,000.00$24.07M
2022-12-31-$6.68M$72,000.00-$6.76M
2022-03-31-$6.38M$6,000.00-$6.38M
2021-12-31-$6.81M$14,000.00-$6.82M
2021-03-31-$3.54M$31,000.00-$3.57M
2020-12-31-$6.06M$46,000.00-$6.11M
2020-03-31-$2.06M$55,000.00-$2.12M
2019-12-31-$2.58M$67,000.00-$2.65M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$190.92M$9.69M-$200.6M
2024-12-31-$110.79M$7.17M-$117.97M
2023-12-31-$7.57M$831,000.00-$8.4M
2022-12-31-$28.69M$248,000.00-$28.94M
2021-12-31-$18.23M$79,000.00-$18.31M
2020-12-31-$12.13M$586,000.00-$12.72M
2019-12-31-$9.6M$233,000.00-$9.83M